News

Fierce Pharma10d
Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug
Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...
Is Novo Nordisk Stock a Buy?
With Wegovy in its portfolio, Novo Nordisk is a very good bet to continue being a winner. As it's currently considered something of an underdog, with its stock priced accordingly, it's also trading at ...
Can anything threaten Novo and Lilly’s obesity market dominance?
Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back ...
Novo Nordisk: The Fear Is Overblown
Novo Nordisk saw a significant decline as it lost over 55% from its highs in June 2024. Check out the reasons for the decline ...
The Best Stock to Buy With Less Than $60 in the Market Sell-Off
One such example is Novo Nordisk ( NVO 2.01%), the Denmark-based pharmaceutical leader whose shares are exchanging hands for just $60 each, and as recently as last July, traded in the mid-140s. Novo ...
24/7 Wall St.11d
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (April 2025)
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Growth Is Priced Out Of Novo Nordisk
Novo Nordisk A/S faces challenges in the obesity market, but new trials and innovations offer hope. Read more on NVO stock ...
Zacks Investment Research on MSN3d
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
Novo Nordisk NVO is expected to beat estimates when it reports its first-quarter 2025 results before the opening bell on May ...